Physician profile
Channing M Smith
NPI 1699795781
$21,503.86
in general payments reported to CMS, 2019-2025
69 companies · $2,670 in 2025
The $2,670 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,020 · 2020: $6,327 · 2021: $2,572 · 2022: $2,463 · 2023: $2,482 · 2024: $2,971 · 2025: $2,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,122.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $4,385.17 | 2019-2025 | Veozah |
| Novo Nordisk INC | $2,593.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,534.52 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $1,518.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,288.08 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,013.29 | 2019-2025 | Vraylar, Ubrelvy, Viberzi |
| Lilly USA, LLC | $815.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $756.59 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $689.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $590.35 | 2019-2025 | Jardiance, Ofev, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $526.77 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Amarin Pharma, INC. | $343.61 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $329.44 | 2019-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $304.93 | 2019-2024 | Qelbree, Xyosted |
| E.R. Squibb & Sons, L.L.C. | $291.96 | 2019-2023 | Eliquis |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Channing Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.